It is fair to say the world has changed in 2020 since the COVID-19 Coronavirus outbreak in December 2019.
Many of our research team have volunteered to work on the NHS frontline at this very busy time but, despite this, Breathing Matters is still continuing its important research work in interstitial lung diseases, pulmonary fibrosis, bronchiectasis and lung infections.
COVID-19 disease is caused by the SARS-Cov-2 virus. SARS means severe acute respiratory syndrome. So, Breathing Matters is joining the national effort in trying to find out as much as possible about this new virus; the more we know, the quicker we will have better treatments, less deaths, decreased shielding and ultimately a vaccine.
Our new studies will include researching new therapeutic agents and understanding the long-term damage to lungs in patients who have recovered from COVID-19, and perhaps give us more insights into the origins of IPF and other fibrotic lung diseases.
The funding we continue to receive from our supporters is vital to our community and to our future. Thank you so much for continuing to support our important work. Donations can be given in different ways: https://www.breathingmatters.co.uk/ways-to-donate
I am sure you would like to join us in saluting our extraordinary team who are working tirelessly in helping the nation, both on the frontline and in the labs.
Our very best wishes goes to every one of you. Please keep safe and stay alert.
Recent Articles
- First new IPF licenced medicine in a decade
- Understanding the biology of PPFE
- Meet this year’s BALR-BM summer student
- How common is muscle loss in lung fibrosis?
- July 2026 Newsletter
- Could a vaccine treat IPF?
- Thanking Edmonton WMC Club for charity of the year support
- Our new merchandise store is LIVE🌍
- Craft stall bulletin, June 2026
- Thank you, Cunningtons LLP, for 2025-26 support
- Life after tuberculosis
- March 2026 Newsletter
- Living with Bronchiectasis Community Days 2026
- Brinsupri™: First medicine licensed for bronchiectasis in the UK
- PET scans offer hope for SSc-ILD patients



